Psoriatic arthritis: secukinumab gives rapid, sustained pain relief

  • McInnes IB & al.
  • Arthritis Res Ther
  • 7 Jun 2018

  • curated by Miriam Davis, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Secukinumab (Cosentyx) provides rapid pain relief that is sustained over 2 years in patients with psoriatic arthritis.

Why this matters

  • Improvement occurs regardless of past response to anti-TNF therapy.

Study design

  • Extension study of randomized, placebo-controlled FUTURE-2 trial, 298 patients with ≥3 tender and ≥3 swollen joints randomly assigned to 300 mg secukinumab, 150 mg secukinumab, or placebo until week 16, when the placebo group was randomly assigned again to 300 or 150 mg until week 104.
  • Funding: Novartis Pharma AG.

Key results

  • Secukinumab gave greater pain relief by visual analog scale than placebo by week 3:
    • −16.9 points; P<.0001 with mg dose>
    • −12.6 points; P<.05 with mg dose.>
    • Effect sustained through week 104.
  • Secukinumab provided greater pain relief by SF-36 bodily pain domain scores than placebo by week 4 (all P<.0001 with or mg doses sustained through week>
  • At week 104:
    • 27.6% of 300-mg group were responders (≥20% improvement from baseline in tender or swollen joints), and
    • 15.6% of 150-mg group were responders.
  • Pain relief occurred regardless of prior anti-TNF exposure.

Limitations

  • Lack of active comparator from week 16.
  • Post hoc analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit